Effect of Clinical Pharmacist-Led Pharmaceutical Care in Major Depressive Disorder
A legfontosabb adatok
- Ki végzi
- Marmara University
- Hol
- Törökország1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 186 fő vett részt
- Kezdés
- 2024. dec. 25.
- Befejezés
- 2026. jún. 30.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
- A vizsgált kezelések
- Clinical Pharmacist-Led Pharmaceutical Care
- A regiszteradat frissítve
- 2026. november 16.
Ki vehet részt
- Életkor
- 18 év – 65 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 10 feltétel megnézéseKevesebb
Ki vehet részt
- Adults aged 18-65 years
- Diagnosis of major depressive disorder (MDD) by a psychiatrist according to DSM-5 criteria
- Receiving maintenance antidepressant treatment for at least one month
- Ability to communicate effectively in Turkish
- Willingness to participate in the study and provision of written informed consent
- Availability to complete the scheduled follow-up assessments
Ki nem vehet részt
- Drug or substance dependence
- History of bipolar disorder, psychotic disorders, or other severe psychiatric disorders that could interfere with study participation
- Active cancer
- Pregnancy
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This randomized controlled trial evaluated the effects of a six-month clinical pharmacist-led pharmaceutical care intervention on medication adherence, beliefs about medicines, and health-related quality of life in adults diagnosed with major depressive disorder (MDD) receiving antidepressant treatment.
A teljes eredeti leírásKevesebb
A total of 186 participants were randomized in a 1:1 ratio to receive either structured pharmaceutical care in addition to usual psychiatric care or usual psychiatric care alone. Of these, 170 participants completed the six-month follow-up.
The intervention included individualized patient counseling, medication review, identification and management of medication-related problems, and telephone follow-up every two weeks.
Medication adherence was assessed using the Medication Adherence Report Scale (MARS-5), beliefs about medicines using the Turkish Beliefs about Medicines Questionnaire (BMQ-T), and health-related quality of life using the EQ-5D-3L and EQ-VAS. Assessments were conducted at baseline, Month 3, and Month 6.
A vizsgálat 2 csoportja
- Clinical Pharmacist-Led Pharmaceutical CareA vizsgált kezelés
Participants assigned to this group received structured clinical pharmacist-led pharmaceutical care in addition to usual psychiatric care for six months. The intervention included individualized patient education and counseling, medication review, identification and management of medication-related problems, monitoring of adverse effects, and telephone follow-up every two weeks.
- Usual Psychiatric CareNincs vizsgálati kezelés, összehasonlításként
Participants assigned to the control group received usual psychiatric care, including routine clinical follow-up and antidepressant treatment as prescribed by their treating psychiatrist. No additional structured clinical pharmacist-led pharmaceutical care intervention was provided during the six-month study period. Outcome assessments were conducted at baseline, Month 3, and Month 6.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Effect of Clinical Pharmacist-Led Pharmaceutical Care on Medication Adherence, Beliefs About Medicines, and Health-Related Quality of Life in Patients With Major Depressive Disorder: A Randomized Controlled Trial
- A regiszteradat frissítve
- 2026. november 16.